Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Actavis renamed as Allergan

This article was originally published in Scrip

Executive Summary

Actavis has now changed its name to Allergan and began trading under its new moniker on the New York Stock Exchange on 15 June. The name change follows the acquisition of Allergan in March 2015 and the approval of the name change by Actavis shareholders on 5 June; it announced its intention to change names in February. The company's US and Canadian generics business is to retain the Actavis name. CEO and president Brent Saunders said, "By adopting the Allergan name, we are ensuring that our corporate identity reflects the transformation of our company within the pharmaceutical industry and our position as a dynamic new breed of company – a leader in growth pharma." The combination of the two firms has created a new top-10 pharma company by revenues.

You may also be interested in...



Allergan’s Ophthalmology Focus Grows Beyond Restasis And Glaucoma

Allergan is building a diverse ophthalmology portfolio with a pipeline of drugs, devices and procedures that could bolster the company’s eye care revenue beyond Restasis and glaucoma medicines.

Allergan's Fishing For Deals, But Don't Expect A Big Catch

Allergan PLC will use its $36bn in after-tax cash and equity from the sale of its generics business to Teva Pharmaceutical Industries Ltd. to reduce debt, buy back shares of its stock, and to acquire companies or assets, but don't expect Allergan to catch any big fish in its dealmaking net.

‘Challenges Ahead’ For Cell And Gene Therapy, Notes Catapult’s New Chairman McCubbin

The ex-GSK supply head Ian McCubbin will join the independent UK organization aimed at advancing cell and gene therapies, but notes issues with scale and manufacturing ahead.

Related Companies

UsernamePublicRestriction

Register

SC028996

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel